Based on the latest quarterly report, "uncy stock forecast 2025" models show EPS climbing toward $1.25, supported by robust cash flow and low debt-to-equity metrics. Technical charts reveal sustained upward momentum above the 200-day moving average. “This micro-cap name is trading at ~cash and significantly below its value, in our view, but we think this hidden gem has a major upside ahead of OLC [oxylanthanum carbonate] approval,” according to the firm, as quoted by TipRanks.com . “Specifically, lead asset, OLC, is a wholly-owned phosphate binding agent currently in late-stage development for hyperphosphatemia, which universally affects CKD [chronic kidney disease] patients. CKD is a blockbuster market with >500K undergoing kidney dialysis (~80% on phosphate binders), driving ~$1.125B in U.S. sales in 2021 ($2.5B globally).” Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Consensus EPS revisions for "uncy stock forecast 2025" have trended upward for three consecutive months, suggesting analyst confidence in profitability growth.